Drug Trial Radar · NCT07559370
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,116
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Victoria Biomedical Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Purdue University
- First posted
- Apr 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
Conditions
- Malaria (Plasmodium Falciparum)
Interventions
Artemether lumefantrine tabletsDrug
There is no difference
Artemether Lumefantrine and Imatinib MesylateDrug
There is no difference
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose of Imatinib (in mg) Required to Eliminate Viable ParasitesTime frame: 48 hours post-first dose
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) by Severity GradeTime frame: Up to Day 35
- Number of Participants with PCR-Corrected RecrudescenceTime frame: Day 35
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Victoria Biomedical Research Institute
Kisumu, Kenya · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.